The use of ⁶⁸Ga‐PSMA PET/CT to stratify patients with PI‐RADS 3 lesions according to clinically significant prostate cancer risk

Abstract

Background: Prostate imaging reporting and data system (PI-RADS) category 3 lesions represent a "gray zone," having an equivocal risk of presenting as clinically significant prostate cancer (csPCa). 68 Ga-labelled prostate-specific membrane antigen ( 68 Ga-PSMA) positron emission tomography/computed tomography (PET/ CT) has been identified as a diagnostic tool that can help to predict cases of primary PCa. We aimed to explore diagnostic value of 68 Ga-PSMA PET/CT for csPCa in PI-RADS 3 lesions to aid in decision-making and avoid unnecessary biopsies.Methods: A total of 78 men with PI-RADS 3 lesions who underwent both 68 Ga-PSMA PET/CT and transrectal ultrasound/magnetic resonance imaging (MRI) fusion-guided biopsy were enrolled. Images were analyzed by respective physicians who were blinded to the pathological results. Receiver operating characteristic (ROC) curve analysis and decision curve analysis were used to evaluate the diagnostic performance of univariate and multivariate analyses.Results: A total of 26/78 men had pathologically confirmed csPCa. A lower ADCT/ ADCCLP (0.65 vs. 0.71, p = 0.018), smaller prostate volume (25.27 vs. 42.79 ml, p < 0.001), lower free prostate-specific antigen/total prostate-specific antigen (0.11 vs. 0.16, p < 0.001), higher PSA level (13.45 vs. 7.90 ng/ml, p = 0.001), higher PSA density (0.40 vs. 0.16 ng/ml 2 , p < 0.001), higher SUVmax (9.80 vs. 4.40, p < 0.001) and SUVT/BGp (2.41 vs. 1.00, p < 0.001) were associated with csPCa. ROC analysis illustrated the improvement in SUVmax and SUVT/BGp compared with all independent and combined clinical features as well as multiparametric magnetic resonance imaging (mpMRI) features for csPCa detection. The net benefits of SUVmax and SUVT/BGp were superior to those of other features, respectively. With cutoff values of 5.0 for SUVmax and 1.4 for SUVT/BGp, the diagnostic sensitivity and specificity for csPCa were 96.2%, 100% and 80.8%, 84.6%, respectively. Conclusion:68 Ga-PSMA PET/CT is potentially capable of stratifying men with PI-RADS 3 lesions according to the presence of csPCa and has better performance than the model established based on clinical and mpMRI features.

Clinical and Radiological Factors for Predicting Clinically Significant Prostate Cancer in Biopsy-Naive Patients With PI-RADS 3 Lesions

“…In relation to this, studies have recently surfaced that 68 Ga-PSMA PET/CT exhibits superior diagnostic value for PI-RADS score 3 patients in identifying csPCa, compared to combined clinical prediction models involving mpMRI. 42 , 43 Unfortunately, our institution currently lacks this equipment. As this hardware is procured in the future, further studies will be conducted.…”

Prediction of clinically significant prostate cancer using a novel 68Ga-PSMA PET-CT and multiparametric MRI-based model

“…On the other hand, emerging evidences have indicated the higher diagnostic ability compared with mpMRI, especially in some specific situations. Yang et al revealed that 68 Ga-PSMA PET-CT may be helpful in risk stratification of men with PI-RADS 3 lesions with better performance than current models based on mpMRI ( 33 ). Besides, the sensitivity and specificity of 68 Ga-PSMA PET-CT to identify the PI-RADS 3 lesions were 96.2% and 80.8%, respectively ( 33 ).…”

“…Yang et al revealed that 68 Ga-PSMA PET-CT may be helpful in risk stratification of men with PI-RADS 3 lesions with better performance than current models based on mpMRI ( 33 ). Besides, the sensitivity and specificity of 68 Ga-PSMA PET-CT to identify the PI-RADS 3 lesions were 96.2% and 80.8%, respectively ( 33 ). In patients with tPSA level of 4–20 ng/mL, PSMA PET-CT was reported to be more accurate than mpMRI.…”